Beta Bionics Announces Start of Home-Use Clinical Trials

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
34
Beta Bionics Announces Start of Home-Use Clinical Trials with the iLet™ Bionic Pancreas System and Receives IDE Approval from the FDA to Expand its Clinical Trials to Include the Senseonics Eversense CGM Integrated into the iLet
  • The Beta Bionics iLet Bionic Pancreas System is now approved for clinical trials in adults with type 1 diabetes (T1D) using two highly accurate continuous glucose monitoring (CGM) systems: the Dexcom CGM and the Senseonics Eversense CGM
  • iLet compatibility with both CGM systems demonstrates unique commitment by Beta Bionics to patient choice, interoperability, and the highest CGM accuracy standards
  • First dosing in adults with T1D with the iLet using the Dexcom CGM and Fiasp ® in PumpCart began in July 2018
  • First children with T1D will be dosed with the iLet using the Dexcom CGM beginning in July 2018
  • First adults with T1D will be dosed with the iLet using the Senseonics Eversense CGM beginning in August 2018

BOSTON, July 12, 2018 (GLOBE NEWSWIRE) -- Beta Bionics, Inc., a medical technology company leveraging life-long, machine-learning, artificial intelligence to develop and commercialize the iLet Bionic Pancreas System — the world’s first fully autonomous bionic pancreas —announced today that the FDA has approved a supplement filed by Beta Bionics to its previously approved investigational device exemption (IDE) expanding ongoing home-use clinical trials testing its new integrated technology, which combines the iLet bionic pancreas and the Senseonics Eversense CGM.

The FDA previously granted IDE approval for clinical testing of the iLet integrated with the Dexcom CGM.  The FDA’s recent approval to begin clinical testing of an Eversense-compatible iLet comes less than three weeks after Senseonics received FDA approval to begin commercial marketing of Eversense in adults with diabetes.  Eversense is the only CGM system to feature an implantable glucose sensor, designed for long-term continuous use for up to three months, a removable and rechargeable transmitter, and on-body vibratory alerts for high and low glucose levels.

“The Senseonics Eversense CGM represents a categorically differentiated CGM choice for people with diabetes, in addition to transcutaneous CGM, and offers new patient preferences that have not previously been possible,” said Ed Damiano, President and CEO of Beta Bionics.

“We’re excited that the Eversense CGM System is now part of this important clinical study and by the work Beta Bionics has done to ensure the compatibility of Eversense with the iLet Bionic Pancreas System,” said Tim Goodnow, President and CEO of Senseonics. “It’s especially important to include another accurate CGM system in this trial to give patients an option. Giving patients a choice is critical, especially when they’re considering the CGM component of their artificial pancreas and whether an implantable, long-term sensor might be a good fit for their needs.”

Beta Bionics has set itself apart as a market leader committed to unprecedented interoperability and patient choice.  The Company has developed its iLet Bionic Pancreas System to be interoperable with multiple insulins (including Humalog®, Novolog®, and Fiasp®), multiple hormones (including dasiglucagon by Zealand Pharma), and now two very different CGM options.  Beta Bionics has again demonstrated its commitment to interoperability and patient choice, in contrast to those companies that have locked their technologies into exclusive arrangements that limit choices for people with type 1 diabetes. 

“Patient choice of two highly accurate and differentiated CGM technologies is good for our kids, good for the T1D community and essential to building an innovative and sustainable business.  With this milestone, Beta Bionics continues its commitment to remaining at the bleeding edge of product innovation for people with diabetes,” said Dr. Damiano.

Just weeks after Beta Bionics received the go-ahead from the FDA, home-use clinical trials began in adults with T1D at the Massachusetts General Hospital (MGH) using the Dexcom-integrated iLet in the insulin-only configuration with Humalog and Novolog and then again, several weeks later, at Stanford University Medical Center using the Dexcom-integrated iLet in the insulin-only configuration with Humalog, Novolog, and Fiasp.  Under the Beta Bionics IDE and newly approved IDE supplement, an additional cohort of adults with T1D will begin using the Eversense-integrated iLet in the insulin-only configuration next month at MGH.

Beta Bionics plans to enter pivotal trials with its final iLet design in 2019 and expects to launch its first product in 2020.  

About the IDE and PMA Process Investigational use of the iLet was approved by the FDA under an investigational device exemption (IDE). An IDE allows testing of an investigational device in a clinical study in order to collect safety and effectiveness data required to support a Premarket Approval (PMA) application to the FDA. An IDE application and any IDE supplement is approved only after extensive review by the FDA of the device and clinical trial design.

About the iLet The iLet bionic pancreas system is a pocket-sized, wearable medical device that autonomously controls blood-sugar levels in people with diabetes. The machine-learning, mathematical dosing algorithms integrated into the iLet were licensed by Beta Bionics from Boston University.  In previous home-use studies in adults and children with T1D, these algorithms demonstrated dramatic improvements in glycemic control relative to the standard of care.  These improvements included significant reductions in blood-glucose levels, reductions in hypoglycemia, and reductions in intersubject and intrasubject glycemic variability ( New England Journal of Medicine . 2014, 371:313-25; Lancet Diabetes and Endocrinology . 2016, 4:233-43; Lancet . 2016, 389:369-80). 

The iLet is initialized by entering body weight only and does not require the patient to count carbohydrates, set insulin delivery rates or deliver bolus insulin for meals or corrections.  The iLet is effectively three medical devices in one.  It can be configured as an insulin-only bionic pancreas, a glucagon-only bionic pancreas, or a dual-hormone bionic pancreas.  The glucagon-only configuration may be helpful in rare, chronic, low blood-sugar conditions, such as congenital hyperinsulinism (CHI) and insulinoma syndrome.  Beta Bionics is committed to obtaining regulatory approval and commercializing all three iLet configurations.

About Beta Bionics Beta Bionics is a for-profit Massachusetts public benefit corporation founded in 2015 to commercialize the iLet, a revolutionary bionic pancreas that is driven by mathematical dosing algorithms, which incorporate machine-learning artificial intelligence to autonomously control glycemia.  These mathematical dosing algorithms were developed in the Damiano Lab at Boston University and refined based on results from home-use clinical trials in adults and children with T1D.  Beta Bionics is a Certified B Corporation™ whose founders—in addition to Ed Damiano—include other parents of children with type 1 diabetes.  Beta Bionics is committed to acting in the best interests of the diabetes community and to profoundly disrupting the diabetes medical device industry by bringing the iLet to market as expeditiously and responsibly as possible.  Beta Bionics is pursuing regulatory approval of its insulin-only bionic pancreas, which will be followed by its dual-hormone system that will also administer a glucagon analog in order to raise blood-sugar levels without the need to consume carbohydrates.

Beta Bionics is headquartered in Boston, Massachusetts with certain operations in Irvine, California. For further information, please visit www.betabionics.com  or follow Beta Bionics Facebook, YouTube, Instagram, LinkedIn and Twitter @BetaBionics.

Beta Bionics Company Contacts Ed Damiano edamiano@betabionics.com  

Ed Raskin eraskin@betabionics.com  

Beta Bionics Investor Relations Contact Jeremy Feffer jeremy@lifesciadvisors.com  

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rehab Equipment Growth Meets a Brutal Access Gap

Updated Category News Views 89

Rehabilitation demand is piling up faster than the equipment can reach people. That is the uncomfortable fact sitting beneath Wissen Research's forecast for a global rehabilitation equipment market rising from $19.1 billion in 2026 to $25.8 billion by 2031, a 6.2% annual growth rate. It is a respectable expansion story, not some rocket-ship fairy tale. More important, it...

Continue Reading
Precision Metal Forming Is Industry's Quiet Backbone

Updated Category News Views 88

A fraction of a millimeter can turn a perfectly good industrial part into an expensive headache. That unglamorous reality sits at the center of Michele Caulfield's discussion of precision metal forming for HelloNation, and it deserves more attention than it usually gets. Investors watching manufacturing tend to chase flashy automation headlines, big aerospace orders, or...

Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home

Updated Category News Views 114

Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...

Continue Reading
DocLinq Takes Aim at Care Gaps Between Office Visits

Updated Category News Views 149

Healthcare's most expensive loose ends often pile up after the appointment ends. DocLinq, launched from Columbia, Maryland, is taking a run at that awkward stretch between office visits, where records sit in separate systems, chronic-care follow-up gets uneven, and patients are expected to remember far more than any human reasonably can. This is not a story about AI...

Continue Reading
Parents Hand Kids Devices Years Before They Intended

Updated Category News Views 286

A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 108

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
Snowrise Targets the Blind Spots in CPG Sales Data

Updated Category News Views 128

A sales total can look healthy while the floorboards are quietly rotting underneath it. That is the uncomfortable CPG problem Snowrise is aiming at: brands know what moved last quarter, but often cannot identify which stores, channels, communities, or promotions actually created the result. Plenty of management teams still steer by topline revenue, net distribution gains,...

Continue Reading
Hanmi Compressor Tests Vietnam Before Wider Expansion

Updated Category News Views 125

Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 36

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 117

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading

Top 5 Most Recently Viewed Articles

Current Trends in Short Interest Impacting PayPal Stock

Updated Category News Views 262

Understanding PayPal Holdings Inc and Its Market Position PayPal Holdings Inc (NYSE: PYPL) remains a prominent player in the digital payments space, continuing to see fluctuations in its market sentiment. Recently, the company has noted a significant increase in short interest as a percentage of float, climbing by 11.57%. This rise has brought the total number of shares...

Continue Reading
WillScot Plans Upcoming Earnings Call and Webcast for Q1

Updated Category News Views 152

WillScot Holdings Corporation to Share Q1 Results WillScot Holdings Corporation, a renowned leader in providing innovative temporary flexible space solutions, has announced its schedule for releasing the financial results for the first quarter of 2025. This eagerly anticipated announcement is set to take place on May 1, 2025, after market close, allowing investors and...

Continue Reading
Denarius' Bold Move: Debentures Target Early Exit

Updated Category News Views 53

Treading Against Debentures: Denarius' Maneuver Denarius Metals Corp. doesn't seem keen on playing it safe with convertible debentures tying up its business. Jaw-dropping numbers in news like this make you stop and wonder: Is this strategy brilliance, or just a roll of the dice? Time-Pressured Decisions Denarius Metals, trading as OTCQX: DNRSF, has kicked off a whirlwind...

Continue Reading
Katten Partners Recognized Among Top Experts in Crypto Sector

Updated Category News Views 185

Katten Partners Shine in Crypto Industry Recognition Katten, a well-respected law firm, has gained significant attention for its leadership in the evolving digital asset landscape. Three of its distinguished partners have been recognized by Citywealth, a leading publication in the private wealth sector, for their exceptional contributions to the cryptocurrency domain. The...

Continue Reading
Anticipating Logitech International's Earnings Success

Updated Category News Views 160

Anticipating Logitech International's Earnings Success Logitech International (NASDAQ: LOGI) is gearing up for its next quarterly earnings announcement, and investors are keenly observing potential developments. As the company prepares to report earnings, expectations are high for positive news regarding financial forecasts and results. Analyst Predictions for Earnings...

Continue Reading